Third, our study screened bufalin as a candidate inhibitor of UBA3 but did not evaluate its pharmacokinetic or pharmacodynamic properties, toxicity or side effects, or synergistic or antagonistic effects with other anti-ICC agents. The gene discussed is UBA3; the disease is intrahepatic cholangiocarcinoma.